S1 Biopharma is a market‐focused company specializing in the discovery, development, and commercialization of drug therapies for Hypoactive Sexual Desire Disorder (HSDD) and related Sexual Dysfunctions. S1’s lead product, Lorexys, is an oral drug seeking to be the first safe and effective treatment approved by the FDA for HSDD in women. Additional products in development will seek to be the first approved for related Sexual Dysfunctions.